Bristol Myers Squibb Company $BMY Shares Purchased by Candriam S.C.A.

Candriam S.C.A. increased its position in Bristol Myers Squibb Company (NYSE:BMY) by 2.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,223,695 shares of the biopharmaceutical company’s stock after acquiring an additional 27,623 shares during the period. Candriam S.C.A.’s holdings in Bristol Myers Squibb were worth $76,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Rayburn West Financial Services LLC acquired a new position in Bristol Myers Squibb during the third quarter valued at $451,000. Ethic Inc. grew its position in Bristol Myers Squibb by 10.0% during the 3rd quarter. Ethic Inc. now owns 298,064 shares of the biopharmaceutical company’s stock worth $18,599,000 after purchasing an additional 27,160 shares during the period. Pictet Asset Management Holding SA grew its position in Bristol Myers Squibb by 0.4% during the 3rd quarter. Pictet Asset Management Holding SA now owns 2,035,236 shares of the biopharmaceutical company’s stock worth $127,002,000 after purchasing an additional 8,549 shares during the period. Leelyn Smith LLC grew its position in Bristol Myers Squibb by 0.8% during the 3rd quarter. Leelyn Smith LLC now owns 59,776 shares of the biopharmaceutical company’s stock worth $3,730,000 after purchasing an additional 464 shares during the period. Finally, Pegasus Asset Management Inc. purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at about $225,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Rothschild & Co Redburn boosted their price objective on Bristol Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Guggenheim reissued a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Daiwa Securities Group lifted their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Piper Sandler cut their price target on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a report on Monday, October 26th. Finally, Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $65.46.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Insider Transactions at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $62.20 on Friday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The stock’s 50 day simple moving average is $62.34 and its 200-day simple moving average is $60.11. The company has a market cap of $127.15 billion, a PE ratio of 13.79, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a 1-year low of $45.26 and a 1-year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. During the same period in the previous year, the business earned $1.63 earnings per share. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is presently 55.88%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.